SEO URLwww.firestrike.ai/deals/arcellx-gilead-sciences-acquisition-2026-8

acquisitionAnnounced · Feb 23, 2026BiotechnologySource · CredibleArticle · Factual

Arcellx · Gilead Sciences

Gilead Sciences acquires Arcellx

David Najork · Founding Software Engineer

Published Apr 29, 2026 · Updated Apr 29, 2026 · 1 min read

ShareX LinkedIn Email

Deal value

$6.6B

Target

Arcellx

NASDAQ: ACLX · Redwood City, California

Acquirer

Gilead Sciences

Full Acquisition

Status

Pending

Gilead Sciences agreed to acquire Arcellx. Reported deal value: $6.6B. Status: Pending. Sector: Biotechnology. Target headquarters context: Redwood City, California, United States.

This page summarizes publicly available information about the transaction as of 2026-02-23. Figures and status may change as filings and press coverage update.

Gilead Sciences , Inc. entered into an agreement to acquire the remaining 88. 50 % stake in Arcellx , Inc. from New Enterprise Associates , Inc., Sr One Capital Fund I Aggregator , LP , fund managed by SR One Capital Management , LP , and others for approximately $6.6 billion on February 22, 2026

Deal timeline

Announced

Feb 23, 2026 · sa.marketscreener.com

Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.

Sector context

This transaction is classified in Biotechnology with a reported deal value of $6.6B. Figures and status may change as sources update.

Sources: sa.marketscreener.com · Primary article · FireStrike proprietary index